Warning: getimagesize(https://magazine.pharmamkt.net/wp-content/uploads/2020/09/logo-group.jpg): failed to open stream: HTTP request failed! HTTP/1.1 404 Not Found in /home/luciamun/public_html/magazine/wp-content/plugins/td-cloud-library/shortcodes/header/tdb_header_logo.php on line 792

The largest community of pharma leaders

Editor's Pick

Top 10 Oncology Drugs 1997 – 2017

Major pharmaceutical companies have invested immense resources into developing innovative treatments for cancer. Since 1997 the list of the best selling oncology drugs has evolved...

20 Best Selling Drugs 2018 by Luca Dezzani

The Complete List and Analysis of the Best Selling Drugs in 2017. All the Top Products in the Pharmaceutical and Biotechnology Industry with detailed...

Need to predict the competitive behavior in the pharmaceutical market

Pharmaceutical companies, in general, tend to neglect the role of competition in strategic analysis, in spite of being in markets where competition plays a...

The Power of Habit – Creating Positive Feedback Loops in Healthcare

Did you know that almost half of all decisions are based on habits? However, that does not mean that we cannot change our habits (and...

Top 10 Pharmaceutical Companies 1997-2017

The list of the best pharmaceutical companies has evolved significantly over the last 20 years. In this analysis revenues were taken into consideration to rank...

Five Debilitating Myths of Digital Pharma Marketing

Five Debilitating Myths of Digital Pharma Marketing Pragmatic, informed digital marketing makes measurable gains in adoption and adherence. By Fred Geyer, Senior Partner at Prophet Digital pharma...

Is there a way of safeguarding the supply of medicines in the case of a ‘no deal’ Brexit?

By Dr. Jonathan Trethowan, Vice President Regulatory and Scientific Policy at PharmaLex Every month, there are 45 million patient packs of medicines transported from the...

New From Gadgets

How AI Will Transform Life Sciences Marketing

Big data and artificial intelligence continues to transform the healthcare industry. Learn how life sciences marketing should prepare for opportunities and implications.

Is Pharma/Biotech M&A Dead?

Published April 26, 2016 M&A in the Pharma and Biotech industries has often been driven by 1. Purchasing molecules that were considered “underpriced” or 2....

Unlearning Old Programming

Albert Einstein is widely credited with saying, “The definition of insanity is doing the same thing over and over again, but expecting different results.”...

Stay on op - Ge the daily news in your inbox

Trending In Mobile

Off-Label Prescribing – A New Worry for the Pharmaceutical Industry

By Neil Grubert, market access specialist, analyst and author. EU Study on Off-Label Prescribing In recent years, the pharmaceutical industry has been concerned by the precedent set...

Cost of Medicines in Context

Published on April 9, 2017 Innovations in the pharmaceutical and biotech industry are bringing amazing changes in the lives of the common people. Debilitating diseases, like...

The History of the Modern Pharmaceutical Industry

The industry as we understand it today, has its origins in the second half of the 19th century. Whilst the scientific revolution of the 17th century had spread ideas of rationalism and experimentation, and the industrial revolution had transformed the production of goods in the late 18th century. The industry that married the two concepts for the benefit of human health was a comparatively late development.

Entertainment

Evaluation of Clinical Trial Costs and Barriers to Drug Development By Luca Dezzani

Source: https://www.linkedin.com/pulse/evaluation-clinical-trial-costs-barriers-drug-luca-dezzani-md/ The complete analysis of the costs and barriers to drug development in 2018. All the expenses to conduct clinical trials and the split by...

Science

Why Too Many Clinical Trials Fail

By Julien Moussalli Market Expansion Lead at IQVIA (LinkedIn: https://www.linkedin.com/in/julien-moussalli-80010349/) A makeover of the $65 billion clinical trials market (1) is well overdue. According to...

Latest Articles

オクタファルマ、NUWIQ®の添付文書に未治療患者での免疫原性のデータを含める更新をFDAが承認と発表

スイス・ラッヘン--(BUSINESS WIRE)--(ビジネスワイヤ) -- オクタファルマは、米国食品医薬品局(FDA)が当社のヒト細胞株由来組み換え型第VIII因子(FVIII)製剤NUWIQ®に対する添付文書の更新を承認したと発表しました。NUWIQ ®は、血友病A患者における出血の予防と治療を目的に承認されています。更新された添付文書には、未治療患者(PUPs)でのNuProtect試験から得た免疫原性のデータが含まれます。 FVIIIインヒビターの発現は、重度血友病Aの未治療患者(PUPs)で最も重篤な治療合併症です。外因性外来FVIIIに対するインヒビターの発現は、治療の効果を低減し、患者の長期的な関節の健康と生活の質に悪影響を与える場合があります。従ってインヒビター発現のリスクを最小限に抑えることは、未治療患者に対する治療判断で考慮すべき重要事項です。 更新されたNUWIQ®の添付文書には、真の未治療患者で単一のFVIII製剤を検討した前向き試験として最大の規模を持つNuProtect試験から得たデータが含まれます。患者は予防またはオンデマンド療法としてNUWIQ®の Source...
2020 Call for Writers

Are you looking to inspire others in the pharma industry through your writing? You’re invited to submit your articles to become a Featured Writer for The Pharmaceutical Marketing Group website.